Model for assessing human papillomavirus vaccination strategies.

Elbasha EH, Dasbach EJ, Insinga RP. · 2007

Read Model for assessing human papillomavirus vaccination strategies. by Elbasha EH, Dasbach EJ, Insinga RP. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2725801.txt.

Introduction

Elbasha, Dasbach, and Insinga modeled in 2007 whether a four-type HPV vaccine could cost-effectively cut cervical cancer, precancerous lesions, and genital warts in the United States. HPV, human papillomavirus, causes cervical and several other cancers and warts in both sexes. Simple cohort models cannot capture herd immunity, the indirect protection when spread falls, so policy needs a dynamic population model.

Their dynamic model tracked infection and disease across the population under several vaccination strategies added to current screening. Routine vaccination of young girls proved cost-effective in the model, and broader strategies could be judged on the same terms. The abstract frames the four-type vaccine as able to reduce cancer, precancer, and wart incidence at acceptable cost.

Catalog record

CREATORElbasha EH, Dasbach EJ, Insinga RP.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2725801

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Model for Assessing Human Papillomavirus Vaccination Strategies By Elamin H. Elbasha, Erik J. Dasbach, Ralph P. Insinga Published in: Emerging Infectious Diseases DOI: 10.3201/eid1301.060438 ABSTRACT A prophylactic quadrivalent vaccine can cost-effectively reduce the incidence of cervical cancer, cervical intraepithelial neoplasia, and genital warts. Human papillomavirus (HPV) causes cervical intraepithelial neoplasia (CIN); cervical, anal, penile, vaginal, vulvar, and head/neck cancers; anogenital warts; and recurrent respiratory papillomatoses, resulting in disease and death in both women and men (1). Cervical cancer incidence and deaths have substantially decreased in countries with organized cervical cancer screening programs (2). However, despite this success, cervical cancer is the second most common malignancy among women and a leading cause of cancer death worldwide, with an estimated 493,000 new cases and 274,000 deaths in 2002 (3). In the United States, public health authorities recommend that girls and women 11–26 years of age be vaccinated with the newly licensed quadrivalent HPV vaccine, Gardasil (Merck & Co., Inc., Whitehouse Station, NJ, USA), to prevent cervical cancer, precancerous and low-grade lesions, and genital warts caused by HPV types 6, 11, 16, or 18. Policymakers will need information on the epidemiologic and economic impact of HPV vaccination to formulate guidelines (4,5). Cohort models provided some of this information but could not fully assess the impact of HPV vaccination (6). In particular, vaccination will not only directly protect through vaccine-derived immunity but also indirectly through herd immunity. To account for these direct and indirect effects, a population dynamic model is necessary (7). Moreover, a dynamic model can evaluate a broader range of vaccination strategies (e.g., vaccination of boys and men). A few dynamic models exists (6,8), but only 1 has examined the cost-effectiveness of bivalent HPV (16/18) vaccination strategies (9). We developed a dynamic model to assess the epidemiologic consequences and cost-effectiveness of alternative quadrivalent HPV (6/11/16/18) vaccination strategies. A Supplementary Appendix describes in detail the model structure and inputs. Specifically, we examined 2 questions: What is the potential impact of a quadrivalent HPV vaccine on HPV infection and disease in the US population? What is the cost-effectiveness of a quadrivalent HPV vaccine program when added to the current standard of care from the perspective of the US healthcare system? METHODS Screening and Vaccination Strategies We assumed that the vaccine will be combined with current screening and HPV disease treatment practices. We defined the reference vaccination strategy to be routine HPV vaccination of girls by age 12 (F12-only) (10). We also examined the following strategies: 1) routine vaccination of girls and boys by age 12 (F&M12), 2) routine vaccination of girls by age 12 and catch-up female vaccination for those ages 12–24 (F12-only+CUF-only), 3) routine vaccination of boys and girls by age 12 years and catch-up female vaccination for those ages 12–24 years (F&M12+CUF-only), and 4) routine vaccination of boys and girls by age 12 and catch-up female and male vaccination for those ages 12–24 (F&M12+CUF&M). Dynamic Model Structure Our dynamic model has demographic and epidemiologic components (11, Supplementary Appendix). The demographic model defines the demographic characteristics of the population being simulated and describes how persons enter, age, and exit various categories. The heterosexually mixing population is divided into 17 age groups. Each age group consists of persons with low, medium, or high sexual activity. Twelve-year-old persons enter the population at a gender-specific and sexual activity–specific rate. Persons then move between successive age groups at an age- and gender-specific rate per year (11). Persons exit the model upon death at an age- and gender-specific per capita death rate per year. Cervical cancer patients have an additional age- and stage-dependent death rate. Patients with CIN or genital warts do not face an additional risk for death. The epidemiologic model simulates HPV transmission and the occurrence of CIN, cervical cancer, and external genital warts in this age-structured population. The acquisition of infection and progression of persons from infection to disease follow a similar natural history structure, as assumed in previous models for HPV 16/18 (6). We also incorporated HPV 6/11 infection and genital warts, and grouped infections into HPV 16/18, HPV 6/11, or HPV 6/11/16/18. We divided the population into distinct epidemiologic categories, according to the person’s status with respect to infection, disease, screening, and treatment (Supplementary Appendix, Figure 1A–B). [Figure: A simplified schematic diagram of human papillomavirus (HPV) infection and disease state transitions, lifetime duration of infection-derived immunity, unvaccinated compartments. A) Persons enter into the susceptible (X) compartment and leave all compartments at sex- and age-specific rate. A susceptible host may be infected by either or both HPV types. A host infected with a given type can also be infected with the other type and move into compartment (Y12). An infected person can clear infection with 1 type and can become immune to that type (Zh) and get infected with the other type (Uh). Infection with and clearance of all types results in lifetime immunity. B) Cervical intraepithelial neoplasia (CIN) develops in females and progresses though several histologic states: infected with a normal cervix; CIN 1; CIN 2; CIN 3; localized, regional, and distant cervical cancer. CIN can regress to normal with or without infection. Genital warts can develop and clear in those infected with HPV 6/11.] Parameters for Estimates and Sources A comprehensive search of the literature was conducted to obtain baseline values for the parameters of the model (Appendix1, Tables 1, 2, and 3). We used age-stratified data to estimate cytology screening rates (12–14). Estimates of cytology screening sensitivities and specificities were based on published studies (15,16). The degree of protection from the vaccine (the proportion of challenges against which a recipient is protected) against incident infection (HPV 6/11 or 16/18) was 90%; against associated disease the degree of protection was 100% (17,18). We assumed the duration of protection was lifelong for the reference case (6) and examined a 10-year duration in sensitivity analyses. We assumed the natural course of disease was unaltered following vaccine failure or loss of vaccine-induced immunity. Because Gardasil is a prophylactic vaccine, we did not include any therapeutic benefits to recipients already infected with the vaccine types. We assumed that up to 70% of 12-year-olds received a 3-dose vaccine (6). Coverage increased linearly from 0% up to 70% during the first 5 years of the program (e.g., 14% in year 1, 28% in year 2) and remained at 70% thereafter. Vaccine coverage for the catch-up program increased linearly from 0% up to 50% during the first 5 years (e.g., 10% in year 1, 28% of unvaccinated in year 2), and the program was eliminated after year 5. We assumed the cost of the HPV vaccine for 3 doses and administration would be US $360 (range $300–$500), consistent with previous analyses (6). All costs were updated to 2005 US dollars. Costs and quality-adjusted life years (QALY) were discounted at 3%. Simulation Method We assessed the epidemiologic impact and cost-effectiveness of each vaccination strategy over a planning horizon of 100 years. We solved the model for the prevaccination steady-state values of the variables and used them as initial values for the vaccination model. Next, we solved the model for the entire time path of the variables until the system approached a steady-state. Validation Analyses We established the face validity of

Read the complete text